Detalhe da pesquisa
1.
Stresses, Strengths and Resilience in Adolescents: A Qualitative Study.
J Prim Prev
; 40(6): 631-642, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31659580
2.
YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer.
Stem Cells
; 32(6): 1437-50, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24648416
3.
Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.
Stem Cells
; 30(7): 1338-48, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22674792
4.
Examining the Characteristics of Patients With Non-Malignant Lung Disease at the Time of Referral to An Inter-Professional Supportive Care Clinic.
Am J Hosp Palliat Care
; 38(11): 1329-1335, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-33823617
5.
Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer.
Expert Rev Mol Med
; 12: e22, 2010 Jul 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-20653987
6.
Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells.
Oncotarget
; 6(24): 20570-7, 2015 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-26011941
7.
Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).
Oncotarget
; 4(2): 329-45, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23593654
8.
Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance.
Cancer Res
; 70(7): 2840-51, 2010 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20332234